Trump Administration Quietly Dismantles Federal Healthcare Safety Agency, Halting Grants and Slashing Staff

Since 2025, the Trump administration has been progressively shrinking the personnel and activities of the Agency for Healthcare Research and Quality, the only federal agency focused on supporting work and research into improving the safety and quality of healthcare. (Photo by Jeffrey Basinger/Newsday via Getty Images)

Newsday via Getty Images

While the rapid dismantling of the U.S. Agency for International Development in 2025 drew widespread attention, the Trump administration has since pursued a far less visible but equally consequential erosion of the Agency for Healthcare Research and Quality (AHRQ). The long-term repercussions of this quiet takedown will likely be felt by patients across the country for decades.

AHRQ Halts at Least 104 Active Grants

For 27 years, AHRQ has served as the sole federal agency dedicated to funding research that improves healthcare safety and quality—a critical mission for anyone who relies on the medical system. An agency analysis estimated that AHRQ-funded studies saved approximately 20,500 lives and $7.7 billion in healthcare costs between 2014 and 2017 alone. This research spans preventing healthcare-associated infections, reducing medical errors, improving medication safety, measuring hospital quality, and developing patient-safety technologies.

With an estimated 250,000 to 400,000 U.S. deaths annually attributed to preventable medical errors and another 75,000 to 99,000 linked to healthcare-associated infections, the stakes are high. However, researchers in these fields now face severe funding uncertainty, exacerbated by parallel cuts to the National Institutes of Health and the Centers for Disease Control and Prevention. On July 15, AHRQ notified grantees that at least 104 awards would not receive continued funding, dealing a significant blow to the research community.

A Year Without New Awards Despite Congressional Funding

The grant halt follows a year-long freeze on new awards. During the current fiscal year, the agency spent less than $15 million of the $345 million appropriated by Congress. Barring an extraordinary surge in spending before the fiscal year ends on September 30, the administration will have effectively disregarded congressional intent—a pattern that has emerged across several health agencies.

In August 2024, the Society for General Internal Medicine sued AHRQ Director Roger Klein, MD, JD, and Health and Human Services Secretary Robert F. Kennedy Jr., JD, alleging that the funding freeze violates the Congressional Budget and Impoundment Control Act of 1974, which reserves spending authority for the legislative branch. Notably, the July 15 letter avoided the term “termination,” using the phrase “not awarded continued funding” instead—a distinction that may influence the pending litigation.

HHS spokesperson Emily Hilliard stated the agency is developing a new “framework” for grants, though details and a timeline remain unclear. Further inquiries to HHS have not yielded additional clarification.

Agency Loses Three-Quarters of Its Workforce

Operational capacity has collapsed alongside funding. Since January 2025, AHRQ has shed roughly 75% of its staff through firings, layoffs, resignations, and reductions in force. Former employees report that by late 2025, vacant seats vastly outnumbered attendees at internal meetings, leaving the agency unable to perform basic functions or respond to external inquiries.

A Long-Standing Goal to Eliminate the Agency

The current strategy mirrors proposals from Trump’s first term. In 2017, the administration’s budget request sought to effectively eliminate AHRQ, but Congress rejected the proposal and preserved the agency’s funding. The second administration has taken a different approach: while Congress again appropriated funds for AHRQ in 2025, the executive branch has simply prevented the agency from spending them.

Uncertain Future Under New Leadership

It remains unclear whether AHRQ will survive as an independent entity. In March 2025, Secretary Kennedy announced plans to fold AHRQ and other HHS agencies into a new Office of Strategy. Director Klein, appointed in July 2025, has offered little public insight into the agency’s direction; his official biography highlights his background as a molecular pathologist and attorney but does not outline a vision for healthcare quality and safety.

Historically, federal health agencies have relied on external advisory committees and scientific peer review to ensure transparency and guide funding decisions. Recent executive orders and Office of Management and Budget rules have systematically weakened these oversight mechanisms, concentrating grantmaking authority in the hands of political appointees.

The danger of such cuts is that healthcare safety infrastructure often operates invisibly until a crisis exposes its absence—much like the dismantling of pandemic preparedness offices prior to 2020 or food-safety programs before the recent surge in foodborne illness outbreaks. The erosion of research into medical errors and hospital safety will inevitably manifest in preventable harm to patients in the years ahead.

Source link